These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 3719055)

  • 1. A nonparametric version of Williams' test for a randomized block design.
    House DE
    Biometrics; 1986 Mar; 42(1):187-90. PubMed ID: 3719055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A note on Shirley's nonparametric test for comparing several dose levels with a zero-dose control.
    Williams DA
    Biometrics; 1986 Mar; 42(1):183-6. PubMed ID: 3719054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple test procedures for dose finding.
    Tamhane AC; Hochberg Y; Dunnett CW
    Biometrics; 1996 Mar; 52(1):21-37. PubMed ID: 8934584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Confidence intervals and p-values for Williams' and other step-down multiple comparison tests against control.
    Channon EJ; McEntegart DJ
    J Biopharm Stat; 2001; 11(1-2):45-63. PubMed ID: 11459442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A non-parametric equivalent of Williams' test for contrasting increasing dose levels of a treatment.
    Shirley E
    Biometrics; 1977 Jun; 33(2):386-9. PubMed ID: 884197
    [No Abstract]   [Full Text] [Related]  

  • 6. Designs for phase I clinical trials with multiple courses of subjects at different doses.
    Fan SK; Wang YG
    Biometrics; 2007 Sep; 63(3):856-64. PubMed ID: 17403103
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonparametric tests for comparing umbrella pattern treatment effects with a control in a randomized block design.
    Lim DH; Wolfe DA
    Biometrics; 1997 Jun; 53(2):410-8. PubMed ID: 9235118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A generalized multihit dose-response model for low-dose extrapolation.
    Rai K; Van Ryzin J
    Biometrics; 1981 Jun; 37(2):341-52. PubMed ID: 7272419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Issues in the design and interpretation of chronic toxicity and carcinogenicity studies in rodents: approaches to dose selection.
    Rhomberg LR; Baetcke K; Blancato J; Bus J; Cohen S; Conolly R; Dixit R; Doe J; Ekelman K; Fenner-Crisp P; Harvey P; Hattis D; Jacobs A; Jacobson-Kram D; Lewandowski T; Liteplo R; Pelkonen O; Rice J; Somers D; Turturro A; West W; Olin S
    Crit Rev Toxicol; 2007; 37(9):729-837. PubMed ID: 17957539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Efficacy and pattern-valence of psychoergic drug / A new method of comparing drugs applied to identical patients in randomized order (author's transl)].
    Lienert GA; Wall KD
    Arzneimittelforschung; 1980; 30(8):1302-6. PubMed ID: 7192147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multivariate slope ratio assay with repeated measurements.
    Hui SL; Rosenberg SH
    Biometrics; 1985 Mar; 41(1):11-8. PubMed ID: 4005369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimal adaptive design in clinical drug development: a simulation example.
    Maloney A; Karlsson MO; Simonsson US
    J Clin Pharmacol; 2007 Oct; 47(10):1231-43. PubMed ID: 17906158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Rank transformations--the connection between nonparametric and parametric statistics].
    Su BH; Shi BZ
    Zhonghua Yu Fang Yi Xue Za Zhi; 1989 Sep; 23(5):274-8. PubMed ID: 2625061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sample size for a dose-response study.
    Patel HI
    J Biopharm Stat; 1992; 2(1):1-8. PubMed ID: 1300202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sample size estimation for the van Elteren test--a stratified Wilcoxon-Mann-Whitney test.
    Zhao YD
    Stat Med; 2006 Aug; 25(15):2675-87. PubMed ID: 16372389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimating the probability of toxicity at the target dose following an up-and-down design.
    Stylianou M; Proschan M; Flournoy N
    Stat Med; 2003 Feb; 22(4):535-43. PubMed ID: 12590412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Planning of clinical trials.
    Boissel JP
    J Intern Med; 2004 Apr; 255(4):427-38. PubMed ID: 15049877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved up-and-down designs for phase I trials.
    Ivanova A; Montazer-Haghighi A; Mohanty SG; Durham SD
    Stat Med; 2003 Jan; 22(1):69-82. PubMed ID: 12486752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160).
    Ogawa H; Kim-Mitsuyama S; Jinnouchi T; Matsui K; Arakawa K
    Hypertens Res; 2009 Jul; 32(7):575-80. PubMed ID: 19444280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A mechanistic, predictive model of dose-response curves for cell cycle phase-specific and -nonspecific drugs.
    Gardner SN
    Cancer Res; 2000 Mar; 60(5):1417-25. PubMed ID: 10728708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.